Concerns about whether Herbalife products can cause fatty liver disease have emerged following reports of liver injury associated with these nutritional supplements. Whilst there is no established evidence linking Herbalife to typical fatty liver disease (hepatic steatosis), published case reports document acute liver injury in some users. Understanding the distinction between fatty liver disease—characterised by fat accumulation in liver cells—and acute hepatotoxicity is essential. This article examines the evidence, explores potential risks, and provides guidance on recognising liver problems and using supplements safely within the UK healthcare context.

Understanding Fatty Liver Disease and Its Causes

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which affects individuals who consume little to no alcohol, and alcoholic fatty liver disease, directly related to excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting a substantial proportion of adults, often associated with metabolic syndrome. (Some organisations now use the term metabolic dysfunction-associated steatotic liver disease [MASLD], which is clinically equivalent to NAFLD for current UK practice.)

The liver normally contains small amounts of fat, but when fat comprises 5% or more of hepatocytes (liver cells), as assessed by histology or imaging, it becomes pathological. Common risk factors for NAFLD include:

• Obesity and being overweight, particularly with central adiposity

• Type 2 diabetes mellitus and insulin resistance

• Dyslipidaemia (elevated cholesterol and triglycerides)

• Metabolic syndrome

Secondary causes of hepatic steatosis (distinct from NAFLD) include:

• Rapid weight loss or malnutrition

• Certain medications (e.g., amiodarone, methotrexate, tamoxifen, corticosteroids, sodium valproate)

• Toxins and excessive alcohol

The pathophysiology involves complex metabolic disturbances. Insulin resistance leads to increased fatty acid delivery to the liver, enhanced hepatic lipogenesis (fat production), and decreased fatty acid oxidation. In some individuals, simple steatosis progresses to non-alcoholic steatohepatitis (NASH), characterised by inflammation and hepatocyte damage, which can ultimately lead to fibrosis, cirrhosis, and hepatocellular carcinoma.

Drug-induced liver injury (DILI) represents another important cause of liver dysfunction. Various medications, herbal medicines, and dietary supplements can cause hepatotoxicity through direct toxic effects, immune-mediated mechanisms, or metabolic idiosyncrasies. The MHRA maintains vigilance over products that may pose hepatotoxic risks, including certain herbal medicines and dietary supplements marketed for weight management or nutritional support.

Can Herbalife Products Cause Fatty Liver?

The relationship between Herbalife products and fatty liver disease is not established through clinical evidence. However, there is documented evidence of hepatotoxicity associated with Herbalife consumption in published case reports and case series, though this typically manifests as acute liver injury rather than classic fatty liver disease. The distinction is clinically important: whilst fatty liver involves fat accumulation (steatosis), Herbalife-associated cases generally present as hepatocellular or cholestatic injury patterns.

Herbalife products are nutritional supplements and meal replacement formulations containing various ingredients including botanical extracts, vitamins, minerals, and proteins. In the UK, most Herbalife products are regulated as food supplements under food law rather than as licensed medicines, meaning they do not undergo the rigorous pre-market clinical trials required for pharmaceuticals. The potential mechanisms for liver injury remain incompletely understood but are hypothesised to include:

• Idiosyncratic drug reactions to specific botanical ingredients

• Contamination or adulteration of products

• Excessive intake of certain vitamins (e.g., vitamin A) or other components

• Interactions between multiple ingredients

• Individual genetic susceptibility affecting metabolism

There is no published evidence linking Herbalife products to the development of typical fatty liver disease characterised by hepatic steatosis. The reported cases involve acute hepatitis-like presentations rather than gradual fat accumulation. Multiple case reports and case series from various countries have documented temporal associations between Herbalife product use and acute liver injury, though establishing definitive causality remains challenging.

The challenge in establishing causality lies in the variability of product formulations across different markets, individual patient factors, concurrent medications, and the difficulty in identifying specific hepatotoxic components among numerous ingredients. Rechallenge data—where symptoms recur upon re-exposure—has been documented in some case reports, strengthening the suspected association. Healthcare professionals should maintain awareness that whilst Herbalife products do not typically cause fatty liver disease per se, they have been implicated in other forms of liver injury.

Reported Cases of Liver Injury Linked to Herbalife

Medical literature contains numerous case reports and case series documenting liver injury temporally associated with Herbalife product consumption. A significant body of evidence emerged from international case series, with notable publications from Israel (2007) and Switzerland (2007–2008), as well as reports from Spain and other European countries, documenting hepatotoxicity patterns ranging from mild transaminase elevations to acute liver failure requiring transplantation.

The clinical presentation in reported cases typically includes:

• Acute hepatocellular injury (elevated ALT and AST)

• Cholestatic or mixed hepatitis patterns

• Jaundice and pruritus

• Fatigue, nausea, and abdominal discomfort

• Onset typically 1–6 months after starting products

• Resolution following product discontinuation in most cases

The Israeli case series, published in the Journal of Hepatology in 2007, documented cases of hepatotoxicity associated with Herbalife products. Liver biopsy findings revealed acute hepatitis with varying degrees of inflammation and necrosis. Importantly, the latency period—time from initiation to symptom onset—varied considerably between individuals, suggesting idiosyncratic rather than dose-dependent toxicity, consistent with patterns seen in drug-induced liver injury.

Causality assessment in these cases has utilised standardised tools such as the Roussel Uclaf Causality Assessment Method (RUCAM). The Spanish drug-induced liver injury (DILI) registry has identified herbal and dietary supplements, including Herbalife, among products associated with serious hepatotoxicity.

Critically, severe outcomes have been documented, including cases requiring liver transplantation. These reports underscore the importance of post-marketing surveillance and the need for healthcare professionals to maintain a high index of suspicion when patients using such products present with unexplained liver enzyme abnormalities.

Recognising Symptoms of Liver Problems

Early recognition of liver dysfunction is crucial for preventing progression to serious complications. Many individuals with liver problems, including early fatty liver disease or drug-induced liver injury, remain asymptomatic initially, with abnormalities detected only through routine blood tests. However, as liver damage progresses, various symptoms may emerge.

Early warning signs of liver problems include:

• Persistent fatigue and malaise

• Right upper quadrant abdominal discomfort or fullness

• Unexplained nausea or loss of appetite

• Mild, intermittent jaundice (yellowing of skin or eyes)

• Dark urine or pale stools

• Generalised pruritus (itching)

More advanced liver disease may present with:

• Pronounced jaundice

• Ascites (abdominal swelling from fluid accumulation)

• Peripheral oedema

• Easy bruising or bleeding

• Confusion or altered mental status (hepatic encephalopathy)

• Spider naevi and palmar erythema

If you are taking Herbalife products or any nutritional supplements and experience any symptoms suggestive of liver dysfunction, you should discontinue the product immediately and contact your GP urgently. This is particularly important if you develop jaundice, as this indicates significant liver impairment requiring prompt medical assessment.

Seek immediate medical attention (attend A&E or call 999) if you experience:

• Jaundice with confusion, drowsiness, or bleeding tendency

• Vomiting blood or passing black, tarry stools

• Severe abdominal pain with distension

• Signs of acute liver failure (jaundice with coagulopathy or encephalopathy)

Your GP can arrange appropriate investigations, including liver function tests (LFTs measuring ALT, AST, ALP, bilirubin, and albumin), to assess liver health. The British Society of Gastroenterology provides guidance on the investigation of abnormal liver blood tests, which may include viral hepatitis screening, autoimmune markers, and imaging studies such as ultrasound to evaluate liver architecture and exclude other pathology.

For individuals with NAFLD, risk stratification for advanced fibrosis is recommended using non-invasive scores such as the Fibrosis-4 (FIB-4) index or NAFLD Fibrosis Score (NFS). Those at high risk may require further assessment with the Enhanced Liver Fibrosis (ELF) blood test or referral to specialist hepatology services, as outlined in NICE guidance.

Safe Use of Nutritional Supplements and Liver Health

The regulation of nutritional supplements differs significantly from pharmaceutical medications, with less stringent pre-market safety testing requirements. In the UK, food supplements are regulated under food law rather than medicines legislation, meaning they do not undergo the rigorous clinical trials required for licensed medicines. This regulatory framework necessitates informed consumer awareness and cautious use.

Principles for safe supplement use include:

• Consult healthcare professionals before starting any supplement regimen, particularly if you have existing liver disease, take regular medications, or have other health conditions

• Inform your GP and pharmacist about all supplements you take, as they may interact with prescribed medications

• Purchase from reputable sources to minimise risks of contamination or adulteration

• Avoid exceeding recommended doses, as more is not necessarily better and may increase toxicity risk

• Be cautious with multiple products, as ingredient overlap may lead to excessive intake of certain nutrients

• Monitor for adverse effects and discontinue products if you develop unexplained symptoms

For individuals with existing liver disease or risk factors for liver problems, particular caution is warranted. The British Liver Trust recommends avoiding unnecessary supplements and herbal products, as the compromised liver may have reduced capacity to metabolise these substances safely. If you have NAFLD, focus should be on evidence-based interventions including weight loss (7–10% body weight reduction can improve liver inflammation and fibrosis), a Mediterranean-style diet, regular physical activity, and management of metabolic risk factors such as diabetes and dyslipidaemia.

NICE guidance on NAFLD management emphasises lifestyle modification as the cornerstone of treatment rather than reliance on supplements. There is currently no licensed pharmacological treatment specifically for NAFLD, though medications for associated conditions (diabetes, dyslipidaemia) should be optimised. Statins are safe and indicated in NAFLD when clinically appropriate for cardiovascular risk reduction.

The MHRA operates a Yellow Card scheme for reporting suspected adverse reactions to medicines (including herbal medicines) and medical devices. If you or your healthcare provider suspect a herbal medicine has caused liver injury or other adverse effects, reporting through this system contributes to pharmacovigilance and helps protect public health. For safety concerns about food supplements (which are not medicines), reports should be made to the Food Standards Agency or local Trading Standards.

Healthcare professionals should maintain a low threshold for investigating liver function in patients using nutritional supplements, particularly those marketed for weight management, and should counsel patients about potential risks alongside any perceived benefits.

Frequently Asked Questions